Jacob Plieth — Catching up with $ZYME pan-RAS inhibitor payload ADCs from #AACR26. Seems the setting for each one is tumours that are RAS-mutated as well as expressing the target antigen (PTK7, L…↗
Jacob Plieth — ADCs (including multiple-payload ADCs) in focus at #AACR26, via @Apexonco -> https://t.co/nyAe5FjV4y $STRO $ALPMF $GSK $ZYME $IPN.PA↗
January 2026 · 1 mention
Jan 2
Jacob Plieth — That's confirmed now - #GI26 late-breaking abstract LBA285 $JAZZ $ONC $ZYME↗
November 2025 · 1 mention
Nov 19
Jacob Plieth — $ZYME becomes more selective in R&D, and moves to royalty aggregation & share buybacks. Via @ApexOnco -> https://t.co/L4SlBx9vZB $RPRX $XOMA↗
October 2025 · 2 mentions
Oct 19
Jacob Plieth — Tubulis succeeds in Napi2b where $MRSN $RHHBY & $ZYME failed. Via @ApexOnco from #ESMO25: https://t.co/NqcAJZMnK9↗
Oct 19
Jacob Plieth — What's Tubulis's Napi2b ADC secret sauce? 50% cORR with TUB-040, per Antonio González-Martín $MRSN $RHHBY $ZYME #ESMO25 https://t.co/75tOveLybZ↗